No Data
No Data
Pharma F Research Memo (12): Shareholder returns are estimated to have a total return ratio of 20%, including share repurchases
■Pharma Foods <2929> Growth Strategy 5. Shareholder return measures Regarding return of profits to shareholders, the basic policy is to actively enhance dividends, etc. as return measures for shareholders while actively expanding investment in research and development, advertising, M&A, etc. under a business policy that balances corporate growth and profitability. Based on this policy, shareholders have a total return ratio of 20%, including share buybacks, taking into account the balance between promoting growth investments, ensuring financial soundness, and strengthening shareholder returns
Pharma F Research Memo (11): Creating new markets in the fields of “textiles,” “battery materials,” and “biostimulants”
■Pharma Foods <2929> Growth Strategy 3. New market creation In the health market, which is an expansion trend, brand strengthening, overseas market development (US market development, Chinese market development through cross-border EC, Southeast Asian market development through halal certification), deepening mail order business in the domestic market (development of new products and services utilizing D2C platforms with over 1 million people), and business model transformation from BtoB to BtoC (major drug company brand products
Pharma F Research Memo (10): Aiming for sales of 100 billion yen for the fiscal year ending 2026/7 with “New Value Creation 1K”
■Growth Strategy 1. The Mid-Term Management Plan 2026 Pharma Foods <2929> sets “New Value Creation 1K” in the “Mid-Term Management Plan 2026” (2022/7 to 2026/7), and aims for sales of 100 billion yen for the 2026/7 fiscal year through efforts to create new value (new products, new markets, new organizations). The breakdown of numerical sales targets is 70 billion yen for growth in existing businesses, 30 billion yen for new value creation, and average sales growth rate by the 2026/7 fiscal year as a commitment
Pharma F Research Memo (8): The BtoB business expanded steadily, and the BtoC business declined but turned into a surplus
■Performance Trends of Pharma Foods <2929> 2. Trends by segment (1) BtoB business In the BtoB business, sales increased 2.5% from the same period last year to 4,171 million yen, and segment profit (operating profit before adjustments for company-wide expenses, etc.) increased 6.1% from the same period last year to 743 million yen. Although shipments of some Meiji Pharmaceutical products were affected by the Reiwa 6 Noto Peninsula Earthquake, sales and profits increased steadily, centering on the main force “Pharma Gaba (R).” Sales by item were the same for functional materials 16.
Pharma F Research Memo (7): The second quarter of the fiscal year ending 2024/7 turned into a surplus
■Financial Trends 1. Consolidated financial results summary for the 2nd quarter of the fiscal year ending 2024/7 Pharma Foods <2929> consolidated financial results for the second quarter of the fiscal year ending 2024/7 were sales of 31,652 million yen, operating income of 1,535 million yen (loss of 883 million yen in the same period last year), ordinary profit of 1,542 million yen (loss of 912 million yen), and quarterly net profit attributable to parent company shareholders was 768 million yen (loss of 914 million yen). As for sales, the BtoB business has steadily expanded
Pharma F Research Memo (5): BtoC business expands product lineups such as “pneumo (R) hair growth agents,” etc., and new products are also growing
■Business Overview 3. BtoC business The BtoC business sells pharmaceuticals/quasi-drugs, supplements, and cosmetics containing functional ingredients unique to Pharma Foods <2929> as a “mail-order business for inventing companies.” The sales form is direct sales to consumers in a mail order form or wholesale sales to shopping specialty channels. Also, Meiji Pharmaceutical's “repeat mail order business” was added from the 2nd quarter of the 2022/7 fiscal year. Sales by category for the fiscal year ending 2023/7 are medical
No Data